Artificial intelligence has shortened drug development from years to just 18 months, the founder of METiS TechBio said, as the AI-driven drug design start-up made its Hong Kong debut on Wednesday amid strong investor appetite for AI-related stocks in the city.“We see ourselves like a SpaceX-style company,” Lai Tsai-Ta, co-founder and CEO of METiS TechBio, who obtained a PhD from the Massachusetts Institute of Technology in the US, said.“We use AI algorithms to design a large number of...